Background: Clinical distinction between advanced essential tremor and tremulous Parkinson's disease can be difficult.
Methods: In selected power spectra of accelerometric postural tremor recordings on the more affected side of 41 patients with essential tremor and 39 patients with tremulous Parkinson's disease being indistinguishable by tremor frequency, peak power or number of harmonic peaks, waveform asymmetry (autocorrelation decay), and mean peak power of all harmonic peaks were computed. Cutoff for essential tremor-Parkinson's disease distinction was determined by receiver operating characteristics. Diagnostic yield was tested in 12 clinically unclear patients with monosymptomatic tremor, subsequently definitively diagnosed with essential tremor (n = 2) or Parkinson's disease (n = 10) by 123-I FP-CIT-single-photon emission computed tomography, fluorodopa-positron emission tomography, or clinical course.
Results: By autocorrelation decay 64%, by mean harmonic peak power 94% (Parkinson's disease > essential tremor) of patients with a definite clinical diagnosis, and 11 of 12 clinically unclear patients were classified correctly.
Conclusions: Mean harmonic power is a useful measure to separate clinically difficult cases of advanced essential tremor from tremulous Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.23672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanism-guided engineering of a minimal biological particle for genome editing.
Proc Natl Acad Sci U S A
January 2025
Innovative Genomics Institute, University of California, Berkeley, CA 94720.
The widespread application of genome editing to treat and cure disease requires the delivery of genome editors into the nucleus of target cells. Enveloped delivery vehicles (EDVs) are engineered virally derived particles capable of packaging and delivering CRISPR-Cas9 ribonucleoproteins (RNPs). However, the presence of lentiviral genome encapsulation and replication proteins in EDVs has obscured the underlying delivery mechanism and precluded particle optimization.
View Article and Find Full Text PDFTopical review: Ocular surface abnormalities in neurodegenerative disorders.
Optom Vis Sci
January 2025
School of Optometry and Vision Science, UNSW Sydney, Sydney, New South Wales, Australia.
Significance: In an aging population, the number of people living with neurodegenerative disease is projected to increase. It is vital to develop reliable, noninvasive biomarkers to detect disease onset and monitor progression, and there is a growing body of research into the ocular surface as a potential source of such biomarkers.
Background: This article reviews the potential of in vivo corneal confocal microscopy and tear fluid analysis as tools for biomarker development.
From Europe to the World: EMA's Leadership in Alzheimer Disease Treatment.
Am J Ther
January 2025
James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH.
Amyotrophic Lateral Sclerosis and Parkinson's Disease: Brain Tissue Transcriptome Analysis Reveals Interactions.
Mol Neurobiol
January 2025
Hebei Medical University-Galway University Stem Cell Research Center, Hebei Medical University, Shijiazhuang, 050017, Hebei Province, China.
This study utilises amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD) human brain samples from the GEO database and employs differential expression gene (DEG) analysis to identify genes that are pivotal in both neurodegenerative diseases. Through in depth GO and KEGG enrichment analyses, we elucidated the biological functions and potential pathways associated with these DEGs. Furthermore, by constructing protein‒protein interaction networks, we highlight the significance of shared DEGs in both cellular physiology and disease contexts.
View Article and Find Full Text PDFCalcium Signalling in Neurological Disorders, with Insights from Miniature Fluorescence Microscopy.
Cells
December 2024
Neural Dynamics Laboratory, Department of Medicine, The University of Melbourne, Melbourne, VIC 3052, Australia.
Neurological disorders (NDs), such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and schizophrenia, represent a complex and multifaceted health challenge that affects millions of people around the world. Growing evidence suggests that disrupted neuronal calcium signalling contributes to the pathophysiology of NDs. Additionally, calcium functions as a ubiquitous second messenger involved in diverse cellular processes, from synaptic activity to intercellular communication, making it a potential therapeutic target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!